{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(12)"],"submitter":["Stambler BS"],"pubmed_abstract":["<h4>Background</h4>Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for unsupervised self-administration to terminate atrioventricular nodal-dependent PSVT. Phase 2 results showed potential safety and efficacy of etripamil in 104 patients with PSVT.<h4>Methods</h4>NODE-301, a phase 3, multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of etripamil nasal spray administered, unsupervised in patients with symptomatic sustained PSVT. After a medically supervised etripamil test dose while in sinus rhythm, patients were randomized 2:1 to receive etripamil 70 mg or place"],"journal":["Circulation. Arrhythmia and electrophysiology"],"pagination":["e010915"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9760458"],"repository":["biostudies-literature"],"pubmed_title":["First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)."],"pmcid":["PMC9760458"],"pubmed_authors":["Stambler BS","Wight D","Haberman R","Ip JE","Bennett M","Shardonofsky S","Anderson JL","Camm AJ","Mondesert B","Plat F","Sager PT","Pandey AS","Damle R","Sterns LD","Potvin D","Coutu B"],"additional_accession":[]},"is_claimable":false,"name":"First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).","description":"<h4>Background</h4>Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for unsupervised self-administration to terminate atrioventricular nodal-dependent PSVT. Phase 2 results showed potential safety and efficacy of etripamil in 104 patients with PSVT.<h4>Methods</h4>NODE-301, a phase 3, multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of etripamil nasal spray administered, unsupervised in patients with symptomatic sustained PSVT. After a medically supervised etripamil test dose while in sinus rhythm, patients were randomized 2:1 to receive etripamil 70 mg or place","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T21:26:18.355Z","creation":"2025-02-19T03:01:33.56Z"},"accession":"S-EPMC9760458","cross_references":{"pubmed":["36441560"],"doi":["10.1161/CIRCEP.122.010915"]}}